Harvard Management Company’s Tenaya Therapeutics TNYA Stock Holding History

Harvard Management Company’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-673,270	Closed	-$1.72M	–	20
2023 Q3	$1.72M	Hold	673,270	–	–	0.19%	15
2023 Q2	$3.95M	Hold	673,270	–	–	0.39%	15
2023 Q1	$1.92M	Hold	673,270	–	–	0.2%	34
2022 Q4	$1.35M	Hold	673,270	–	–	0.17%	38
2022 Q3	$1.95M	Hold	673,270	–	–	0.24%	35
2022 Q2	$3.79M	Hold	673,270	–	–	0.44%	26
2022 Q1	$7.93M	Hold	673,270	–	–	0.8%	18
2021 Q4	$12.8M	Hold	673,270	–	–	1.2%	14
2021 Q3	$13.9M	Buy	+673,270	New	+$14.5M	0.81%	19

Other funds holding TNYA

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harvard Management Company's TNYA Position: Q4 2023 in Review

Harvard Management Company sold out of Tenaya Therapeutics (TNYA) in Q4 2023, closing a stake of 673,270 shares — an estimated $1.72M sold.

Harvard Management Company first reported a position in TNYA in Q3 2021 and held it in 9 quarters. The position peaked at $13.9M in Q3 2021. 74 funds tracked by Wall St. Rank hold TNYA as of Q4 2023.

Harvard Management Company reported no remaining Tenaya Therapeutics position as of Q4 2023 after selling out during the quarter.
Harvard Management Company sold 673,270 Tenaya Therapeutics shares in Q4 2023, an estimated $1.72M.
Harvard Management Company first reported a position in Tenaya Therapeutics in Q3 2021 and held it in 9 quarters.
Harvard Management Company's Tenaya Therapeutics position peaked at $13.9M in Q3 2021.
74 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2023.

Based on Harvard Management Company's 13F filing for Q4 2023, filed 9 Feb 2024.